Updated:
Emmaus Life Sciences, Inc.
Emmaus Life Sciences Inc. is a biopharmaceutical company developing treatments for rare diseases, with FDA-approved Endari for sickle cell disease.
Emmaus Life Sciences, Inc.
Emmaus Life Sciences was founded to address unmet medical needs in rare diseases, with a primary focus on sickle cell disease. The company's lead product, Endari (L-glutamine oral powder), received FDA approval in 2017 for reducing complications associated with sickle cell disease in adult and pediatric patients aged five years and older. The firm's founding and operations are centered on advancing this therapy, with clinical research also exploring Endari's potential in other indications such as diverticulosis and thalassemia. The company's strategy involves a combination of direct commercialization in the US and licensing agreements abroad. Endari is marketed in the US by Emmaus' own sales force, targeting hematologists and sickle cell treatment centers. Internationally, Emmaus has entered into distribution and license agreements covering markets including the Middle East, North Africa, and parts of Asia. For example, in 2021, the firm announced a partnership with Medison Pharma to commercialize Endari in Israel. The company has also pursued additional pipeline assets, including early-stage research into therapies for other rare blood disorders. Emmaus is publicly traded on the OTC Markets Group under the ticker EMMA, with a market capitalization that fluctuates based on commercial performance and regulatory milestones. The company's team size, offices, and exact financials are not widely publicized, but it operates as a lean commercial biotech with a focus on Endari's market penetration. No significant recent activity has been reported in the last 24 months beyond ongoing commercial operations and international expansion efforts. The firm's structural differentiator lies in its orphan drug focus with a single approved product, relying on FDA orphan drug exclusivity and market access for a niche patient population. Its public-company status subjects it to SEC reporting, but the firm functions similarly to a small-cap biotech rather than a family office or asset manager. The name 'Emmaus Life Sciences, Inc.' suggests a corporate entity, not a wealth management vehicle.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
Who runs investment decisions at Emmaus Life Sciences?
As a publicly traded company, strategic and investment decisions at Emmaus Life Sciences are made by its board of directors and executive management team. The company's officers are disclosed in SEC filings, but the specific CEO or CFO overseeing capital allocation decisions may change over time (per public SEC filings).
What is Endari and how does it work?
Endari is a prescription medical food containing L-glutamine, an amino acid, approved by the FDA in 2017 to reduce acute complications of sickle cell disease. It is taken orally and works by increasing the level of NAD+ in red blood cells, which may reduce oxidative stress and improve cell health (per FDA prescribing information).
Is Emmaus Life Sciences a family office or an asset manager?
Emmaus Life Sciences is neither a family office nor an asset manager; it is a publicly traded biopharmaceutical company focused on drug development and commercialization. The firm's structure is that of a corporate entity listed on the OTC markets, not a wealth management vehicle (per SEC classification).
Does Emmaus have any approved products besides Endari?
As of the latest available information, Endari is the only FDA-approved product marketed by Emmaus Life Sciences. The company has conducted clinical trials for Endari in other indications, such as diverticulosis and thalassemia, but no additional approvals have been secured to date (per clinicaltrials.gov and company press releases).
Where is Emmaus Life Sciences headquartered?
The firm's exact headquarters location is not publicly documented in the available sources, but it operates primarily in the United States. As a publicly traded entity, its address is typically listed in SEC filings, which may be found in the company's 10-K or 10-Q reports (per public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: